Table K15Comparison of PCA3 and externally validated nomograms (EVN) in central estimates in men with positive and negative prostate biopsy results, after accounting for study-specific variability in measurements

Study/ AuthorbYearNEVNPCA3 score Median for Pos BxPCA3 score Median for Neg BxPCA3 score Median Pooled Log SDPCA3 ZPCA3aEVN score Median for Pos BxEVN score Median for Neg BxEVN score Median Pooled Log SDEVN ZEVNaZPCA – ZEVN
Perdona62011218Chun's “risk”72.022.00.42641.21544118.90.690.52
Perdona62011218PCPT “risk”72.022.00.42641.21543915.20.990.22

Bx = prostate biopsy. Pos = prostate biopsy positive, Neg = prostate biopsy negative; Bx = prostate biopsy, SD = standard deviation

a

Z score = (log (Pos median) – log (Neg median)) / pooled log SD

b

Shaded rows indicate studies focusing on the ‘grey zone’ of tPSA.

From: Appendix K, Summary of the Remaining Combined Analyses for KQ 1 and KQ 2

Cover of PCA3 Testing for the Diagnosis and Management of Prostate Cancer
PCA3 Testing for the Diagnosis and Management of Prostate Cancer [Internet].
Comparative Effectiveness Reviews, No. 98.
Bradley LA, Palomaki G, Gutman S, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.